Royalty Pharma plc (RPRX) Stock Price & Analysis
Royalty Pharma plc (RPRX) closed at USD 63.75 on Thursday, October 22, 2026, up 2.57% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 62.15; the Oct 22, 2026 session ranged USD 62.38–63.84 on volume of 2,808,458 shares. Market capitalization is $36.84B, with a 52-week range of USD 35.92–64.38 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:48 UTC.
Also available as compact Markdown for AI agents: nexqual.com/RPRX.md
Key facts (RPRX)
- Last four reported quarters (through Jun 30, 2026): revenue $2.54B, net income $815M (32.1% margin) (SEC filings).
- Valuation: P/E 45.2x (avg 20.3x at the last 3 fiscal year-ends), EV/EBITDA 29.6x, net debt $8.12B.
- 3 of 80 tracked superinvestors hold RPRX (13F, Q2 2026): 0 new, 1 added, 2 reduced, 0 unchanged.
- Analysts: Buy (mean 1.88 on a 1–5 scale) (8 analysts), mean target USD 65.38 (range 61–70).
- Total return with dividends: 1Y +76.3% vs S&P 500 +14.9%; 5Y +91.1% vs S&P 500 +80.3%.
- Next earnings: 2026-11-04, EPS estimate USD 1.18, revenue estimate $885M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (RPRX)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $2.29B | $2.24B | $2.35B | $2.26B | $2.38B | $2.54B |
| Operating income | $1.43B | $307M | $1.49B | $1.29B | $1.56B | $1.51B |
| Net income | $620M | $42.8M | $1.13B | $859M | $771M | $815M |
| EPS (diluted) | $1.49 | $0.10 | $2.53 | $1.91 | $1.78 | — |
| Operating margin | 62.5% | 13.7% | 63.4% | 57.1% | 65.6% | 59.6% |
| Net margin | 27.1% | 1.9% | 48.2% | 37.9% | 32.4% | 32.1% |
| Revenue growth | +7.9% | -2.3% | +5.2% | -3.9% | +5.1% | — |
| Cash + short-term investments | $1.61B | $1.71B | $495M | $987M | $637M | — |
| Total debt | $7.10B | $7.12B | $6.14B | $7.61B | $8.95B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (RPRX)
P/E 45.2x · P/S 14.5x · EV/EBITDA 29.6x · EV/Sales 17.7x · P/B 3.8x · Earnings yield 2.21% · Buyback yield (TTM) 0.87% · Net debt $8.12B · EV $45.0B
P/E at fiscal year-ends: Dec 2025 28.3x, Dec 2024 17.6x, Dec 2023 14.9x.
Superinvestors (SEC 13F-HR, Q2 2026) (RPRX)
3 of 80 tracked investors hold RPRX. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Pat Dorsey | Dorsey Asset Management | 8.82% | $138M | Added +7.9% |
| Samantha McLemore | Patient Capital Management | 6.70% | $202M | Reduced -1.2% |
| Torray Funds | 4.55% | $33.8M | Reduced -6.7% |
Analysts (RPRX)
Consensus Buy (mean 1.88 on a 1–5 scale), 8 analysts; mean target USD 65.38 (low 61, high 70).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-07 | Morgan Stanley | Target raised | Overweight | $65 → $67 |
| 2026-09-08 | TD Cowen | Target raised | Buy | $65 → $68 |
| 2026-08-07 | JP Morgan | Target raised | Overweight | $58 → $62 |
| 2026-07-13 | TD Cowen | Target raised | Buy | $50 → $65 |
Total return (dividends reinvested) (RPRX)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +76.3% | +91.1% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +76.7% | +13.8% |
| Volatility (annualized) | 23.6% | 21.9% |
| Max drawdown | -12.1% (Sep 2026→Oct 2026) | -40.1% (Aug 2022→Dec 2024) |
RPRX revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Income from financial royalty assets | $638.0M | 94.6% | +15.9% |
| Other royalty income and revenues | $36.1M | 5.4% | +27.9% |
| Total revenue | $674.1M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
RPRX suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) | “(2)We entered into a funding agreement with Teva Pharmaceuticals for TEV-'408 in January 2026.” |
| Partner | CYTOKINETICS INC (CYTK) | “In May 2024, we expanded our funding collaboration with Cytokinetics, Incorporated ("Cytokinetics").” |
| Partner | RPI EPA Vehicle | “An exchange agreement entered into by, among others, Royalty Pharma plc, RP Holdings, the Continuing Investors Partnerships, RPI International Partners 2019, LP, RPI US Feeder 2019, LP, RPI International Feeder 2019, LP, RPI EPA Vehicle, LLC and certain recipients nominated by the Sellers (as amended from time to time, the "Exchange Agreement") facilitates the exchange of RP Holdings Class E Interests and the exch…” |
| Partner | Pfizer (PFE) | “Avillion I is eligible to receive fixed payments from Pfizer based on this approval under its co-development agreement with Pfizer.” |
| Competitor | AbbVie (ABBV) | “•Imbruvica – Royalty Receipts from Imbruvica, which is marketed by AbbVie and Johnson & Johnson for the treatment of blood cancers and chronic graft versus host disease, decreased by $20.7 million in 2025 as compared to 2024, reflecting competitive pressures and the impact of Medicare Part D redesign.” |
| Competitor | Johnson & Johnson (JNJ) | “•Imbruvica – Royalty Receipts from Imbruvica, which is marketed by AbbVie and Johnson & Johnson for the treatment of blood cancers and chronic graft versus host disease, decreased by $20.7 million in 2025 as compared to 2024, reflecting competitive pressures and the impact of Medicare Part D redesign.” |
Quoted from the company's 10-K filed Feb 11, 2026.
Companies that name RPRX in their SEC reports
| Relationship to RPRX | Company | Filing | Sentence |
|---|---|---|---|
| partner | Minerva Neurosciences, Inc. (NERV) | 10-K Mar 11, 2026 | “On January 19, 2021, we entered into an agreement with Royalty Pharma under which Royalty Pharma acquired our royalty interest in seltorexant for an upfront payment of $60 million and up to $95 million in future milestone payments that are contingent upon the achievement of certain clinical, regulatory and commercial milestones for seltorexant by Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companie…” |
| partner | Denali Therapeutics Inc. (DNLI) | 10-K Feb 26, 2026 | “In December 2025, we entered into a royalty funding agreement with Royalty Pharma.” |
| supplier | BeOne Medicines Ltd. (ONC) | 10-K Feb 26, 2026 | “A significant portion of our rights to receive certain tiered mid-single digit royalty payments based on annual net revenue from sales outside of China of IMDELLTRA were sold to Royalty Pharma in the third quarter of 2025.” |
| partner | PTC THERAPEUTICS, INC. (PTCT) | 10-K Feb 19, 2026 | “Pursuant to Amendment No. 2, we sold to Royalty Pharma our retained right to receive sales-based royalty payments, or the Royalty, on worldwide net sales of Evrysdi and any other product developed pursuant to the SMA License Agreement under the SMA Program in exchange for $240.0 million in upfront cash consideration, and three potential additional cash purchase price payments of $20.0 million each conditioned upon…” |
| partner | EXELIXIS, INC. (EXEL) | 10-K Feb 10, 2026 | “Accordingly, and consistent with our historical agreement with GSK, we are required to pay a 3% royalty to Royalty Pharma on total net sales of any product containing cabozantinib, including net sales by Ipsen.” |
| partner | TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) | 10-K Feb 3, 2026 | “In line with our Pivot to Growth strategy, and our focus on internal growth that leverages our R&D capabilities, we have entered into, and expect to pursue, in-licensing, acquisition, collaboration, funding and other strategic opportunities to supplement and expand our existing innovative medicines and biosimilar pipeline (e.g., the transactions with mAbxience, Launch Therapeutics, Alvotech, Modag, Sanofi, Royalty…” |
RPRX company outlook (results filed Aug 5, 2026)
- “The above Portfolio Receipts guidance provided on August 5, 2026 includes expected Royalty Receipts growth of 7% to 10% in 2026.”
- “Royalty Pharma's full year 2026 guidance reflects an estimated foreign exchange impact of approximately +1% to Portfolio Receipts, assuming current foreign exchange rates prevail for the rest of 2026.”
- “Payments for operating and professional costs in 2026 are expected to decrease as a percentage of Portfolio Receipts, compared to 8.9% in 2025, primarily due to extinguishment of the management fee following the completion of the internalization transaction on May 16, 2025.”
- “In 2026, Royalty Pharma anticipates interest paid to be approximately $350 million to $360 million.”
Quoted word-for-word from the SEC 8-K results press release.
RPRX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $1.18 | $1.13 | +4.5% | $884.8M | 6 |
| Next quarter (ends Dec 2026) | $1.52 | $1.49 | +2.3% | $942.0M | 5 |
| Current fiscal year (ends Dec 2026) | $5.32 | $5.23 | +1.8% | $3.51B | 6 |
| Next fiscal year (ends Dec 2027) | $5.81 | $5.59 | +3.9% | $3.82B | 6 |
Key Statistics (as of October 23, 2026 at 09:48 UTC)
| Price | USD 63.75 |
|---|---|
| Change | ▲ 2.57% (up) |
| Previous Close | USD 62.15 |
| Open | USD 62.81 |
| Day Range | USD 62.38 – 63.84 |
| 52-Week Range | USD 35.92 – 64.38 |
| Volume | 2,808,458 shares |
| Market Cap | $36.84B |
| Exchange | NMS |
Technical Analysis (RPRX)
Nexqual's technical model rates RPRX "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:48 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 65.05 (neutral) |
| vs SMA50 | Above (USD 59.61) |
| MACD | 0.87 (positive) |
Analyst Ratings (RPRX)
Wall Street analysts rate RPRX "Buy" based on 8 analysts, with a mean price target of USD 65.38 (range USD 61–70), per Nexqual as of October 23, 2026 at 09:48 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 65.38 |
| High Target | USD 70 |
| Low Target | USD 61 |
| Buy / Hold / Sell | 7 / 1 / 0 |
Earnings (RPRX)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD 1.18 |
| Revenue Estimate | $884.84M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.32 vs est 1.27 ▲ beat |
| 2026-03-31 | USD 1.3 vs est 1.18 ▲ beat |
| 2025-12-31 | USD 1.47 vs est 1.33 ▲ beat |
| 2025-09-30 | USD 1.17 vs est 1.04 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
Financials & Fundamentals (RPRX)
| Total Revenue | $2.54B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +16.50% |
| Gross Margin | +95.82% |
| Operating Margin | +19.75% |
| Profit Margin | +32.02% |
| ROE | +13.96% |
| Debt / Equity | 0.92 |
| Current Ratio | 2.8 |
| Total Cash | $836.99M |
| Total Debt | $8.96B |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
Financial Health Score (RPRX)
Nexqual rates Royalty Pharma plc's overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:48 UTC.
| Growth | Strong — Revenue +16% YoY (annual) |
|---|---|
| Profitability | Solid — Operating margin 20% |
| Balance Sheet | Mixed — $837M cash and investments vs $8.96B debt (Jun 2026, SEC) |
| Cash Flow | Solid — Operating cash flow $2.49B (FY ended Dec 2025, 10-K) |
| Efficiency | Mixed — ROE 14%, ROA 5.1% |
Ownership (RPRX)
| Insider Ownership | +6.49% |
|---|---|
| Institutional Ownership | +87.79% |
| Shares Outstanding | 445.28M |
| Float | 417.58M |
| Short % of Float | +2.93% |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
Leadership (RPRX)
Royalty Pharma plc is led by Pablo Legorreta, Founder, Chairman of the Board & CEO, per Nexqual as of October 23, 2026 at 09:48 UTC.
| Founder, Chairman of the Board & CEO | Pablo Legorreta |
|---|---|
| Executive VP & CFO | Terrance P. Coyne |
| Chairman of Partnering & Investments | Christopher Hite |
| Executive Vice President of Partnering & Investments | Greg Butz |
| Senior VP & Chief Technology Officer | Eric Cornelius Schneider |
Major Backers & Investors (RPRX)
Notable institutional backers of Royalty Pharma plc include Morgan Stanley, Capital International Investors, FMR, LLC, according to Nexqual as of October 23, 2026 at 09:48 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 9.64% |
| Capital International Investors | 7.92% |
| FMR, LLC | 5.51% |
| NEW PERSPECTIVE FUND | 4.34% |
| Price (T.Rowe) Associates Inc | 2.51% |
| Swedbank AB | 2.41% |
| Baillie Gifford | 2.25% |
| Capital Group | 2.14% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.25% |
| State Street | 2.77% |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
From Royalty Pharma plc's Latest SEC 10-K Filing (filed 2026-02-11)
Key Strengths & Strategy (as disclosed to the SEC)
- We have executed 13 of these 21 large transactions, for a total transaction value of approximately $12.7 billion and an estimated market share of 69% based on the transaction value.
- We have end-to-end capabilities that span clinical and commercial analysis, valuation and transaction structuring.
- We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry.
- Our highly selective investment approach focuses on identifying and tracking important new therapies, which allows us to act efficiently when opportunities arise.
Partnerships
- We are entitled to 25% of Ionis' Spinraza royalty payments of 11% to 15% on sales up to $1.5 billion through 2027, increasing to 45% of royalty payments on sales up to $1.5 billion in 2028. (9)We are entitled to royalties on worldwide net sales of Imdelltra, excluding sales in China.
Legal & Regulatory Risks (Item 1A, quoted)
- The manufacture and distribution of a biopharmaceutical product may be interrupted by regulatory agencies or supplier deficiencies.
- Product liability claims may diminish the returns on biopharmaceutical products.
- The EU directive on alternative investment fund managers (the "AIFM Directive") may significantly increase our compliance costs.
- Legal claims and proceedings could adversely affect our business.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RVMD | Revolution Medicines, Inc. | USD 187.69 | ▼ 3.39% |
| ONC | BeOne Medicines Ltd. | USD 382.27 | ▼ 1.08% |
| ALNY | Alnylam Pharmaceuticals, Inc. | USD 227.28 | ▲ 0.97% |
| ROIV | Roivant Sciences Ltd. | USD 37.45 | ▲ 1.77% |
| GMAB | Genmab A/S | USD 40 | ▲ 1.09% |
| ARGX | argenx SE | USD 875.76 | ▼ 1.61% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:48 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt